|Chemical and physical data|
|Molar mass||349.434 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
MDA-19 (also known as BZO-HEXOXIZID) is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. In animal studies it was effective for the treatment of neuropathic pain, but did not effect rat locomotor activity in that specific study. The pharmacology of MDA-19 in rat cannabinoid receptors have been demonstrated to function differently than human cannabinoid receptors with MDA-19 binding to human CB1 receptors 6.9x higher than rat CB1 receptors.
MDA-19 was first synthesized and studied in the late 2000s by researchers at the University of Texas M. D. Anderson Cancer Center. 
MDA-19 binds to human CB2 receptors at Ki = 43.3 +/- 10.3 nM and human CB1 receptors at Ki = 162.4 +/- 7.6 nM and functions as an agonist in human cannabinoid receptors but functions differently in rat cannabinoid receptors binding to rat cannabinoid CB2 receptors at Ki = 16.3 +/- 2.1 and CB1 receptors at Ki = 1130 +/- 574 nM binding to rat CB1 recptors 6.9x weaker than human CB1 receptors but increased binding for CB2. MDA-19 is an agonist at human CB1 and CB2 receptors as well as rat CB1 receptors but functions as an inverse agonist in rat CB2 receptors.
MDA-19 along with its shortened Pentyl tailchain analog (MDA-19-Pentyl / 5C-MDA-19/ BZO-POXIZID) and it's 5-Fluoro Pentyl analog (5F-MDA-19 /5F-BZO-POXIZID) and it's Cyclohexylmethyl analog (CHM-MDA-19 / BZO-CHMOXIZID) was identified in synthetic smoke blends seized in the United States as early as September 2021. Despite its reported low CB1 binding affinity. Other low CB1 binding synthetic cannabinoids such as UR-144 (Ki = 150nM CB1 and Ki = 1.8nM CB2) and XLR-11 (EC50 values of 98nM CB1 and 83nM CB2) have been previously identified in smoke blends in 2012.
As of November 2021 MDA-19 is legal in the United States but may be considered illegal if intended for human consumption under the federal analog act. In China, the May 2021 ban on specific synthetic cannabinoid core classes does not include the class of cannabinoids MDA-19 belongs to.